Board of Directors
- Anne Wojcicki
- CEO and Co-Founder
Anne co-founded 23andMe in 2006, three years after the first human genome was sequenced. Her goal was audacious: to help people access, understand, and benefit from the human genome and fundamentally change healthcare in the process. Prior to founding 23andMe, Anne spent a decade on Wall Street investing in healthcare and felt frustrated by a system built around monetizing illness instead of incentivizing prevention. She wanted to flip that model on its head and build a business that helps people prevent illness rather than profit from it. Anne focused on empowering people with direct access to genetic information so that they could use their data to make decisions that could lower their risks for disease. Under her leadership, 23andMe now provides the only personal genetic test with FDA authorization to deliver health information directly to consumers.
From the beginning, Anne's goal and 23andMe’s mission has not wavered. Along with empowering consumers with health information, Anne wanted 23andMe to transform how research discoveries are made and revolutionize the development of treatments for disease. By inviting people to participate in research, 23andMe is able to crowdsource billions of data points resulting in the world’s largest resource for genetic research. This novel, web-based approach has already resulted in thousands of new genetic insights and allows 23andMe to rapidly recruit participants to multiple studies at once, reducing the time and resources needed to make discoveries and is integral to 23andMe’s mission of understanding and benefiting from the human genome This new approach to research also powers 23andMe’s therapeutics group, which is helping to translate this knowledge into new treatments for serious unmet medical needs. In line with this, 23andMe is now also using its unique model to speed recruitment for clinical trials.
Anne is a pioneer in the direct-to-consumer DNA testing space and her vision and persistence have allowed 23andMe to provide people with unprecedented access to genetic information. Through its research platform, 23andMe has brought personalized medicine directly to millions of consumers.
Anne graduated from Yale University with a BS in Biology.
- Neal Mohan
- Board Member
Neal Mohan is Chief Product Officer at YouTube, and a SVP at Google. He is responsible for YouTube products and user experience on all platforms and devices globally. This includes YouTube’s core mobile applications, YouTube.com, emerging technologies like VR, vertical experiences such as YouTube Kids, Music and Gaming, and YouTube’s two subscription services, YouTube Red and YouTube TV. Products for media partners, content creators and musicians are also part of Neal’s portfolio.
Previously, Neal was Senior Vice President of Display and Video Ads at Google. In this role, he was responsible for the company’s advertising offerings on YouTube, the Google Display Network, AdSense, AdMob, and the DoubleClick family of programmatic ad platform products. He focused on growing the overall digital media industry by building innovative solutions for millions of Google's advertising and media partners around the world.
Neal serves on the Boards of Directors for 23andMe and the New America Foundation’s California Advisory Council. He has also served as a member of the Management Board for the Stanford Graduate School of Business. Neal has been a member of the Board of Directors for the Internet Advertising Bureau and the Mobile Marketing Association. He is a regular speaker at media and technology industry events and has been named one of Ad Age's 10 Most Influential Players in Marketing and AdWeek’s 12 Stars of Ad Tech.
Before joining Google, Neal was Senior Vice President of Strategy and Product Development at DoubleClick where he built the company's strategic plan, led the product management team, and rapidly grew the business. He played a critical role in the sale of DoubleClick to Google and subsequently led the integration. Previously, Neal held various technology and business leadership positions at DoubleClick and NetGravity where he helped pioneer the digital marketing industry. He has also served in strategy and consulting roles at Microsoft and Accenture.
Neal earned an MBA from the Stanford Graduate School of Business where he was an Arjay Miller Scholar. He also holds a bachelor’s degree in electrical engineering from Stanford University.
- Roelof Botha
- Board Member
- Richard Scheller, Ph.D.
- Board Member
Richard H. Scheller joined 23andMe in 2015 as Chief Scientific Officer and Head of Therapeutics. Under his leadership, 23andMe built a dedicated research and therapeutic development team that uses human genetic data as the starting point for identifying novel therapies for common and rare diseases. Richard was appointed to the board of directors in early 2019.
For 14 years Scheller was Executive Vice President and Head of Genentech Research and Early Development, and member of both the Genentech and Roche executive committees. Prior to joining Genentech, Scheller was a professor of Biological Sciences at Stanford University (1982-1994), and was a Howard Hughes Medical Institute investigator at the Stanford University School of Medicine from 1994 to 2001. Scheller has been an adjunct professor of Biochemistry and Biophysics at UC San Francisco since 2004. He is a member of the board of trustees at the California Institute of Technology.
Scheller’s research elucidating the molecular machinery and regulatory mechanism that underlie the release of neurotransmitter earned him the 2013 Albert Lasker Basic Medical Research Award, the 2010 Kavli Prize in Neuroscience, and the 1997 US National Academy of Sciences Award in Molecular Biology.
Scheller is a fellow of the American Academy of Arts & Sciences, a member of the National Academy of Sciences, and a member of the National Academy of Medicine. Scheller holds a Bachelor of Science in Biochemistry from University of Wisconsin-Madison and a Ph.D. in Chemistry from the California Institute of Technology. He was a postdoctoral fellow in the Division of Biology at the California Institute of Technology and a postdoctoral fellow in Molecular Neurobiology at Columbia University at the College of Physicians and Surgeons.
- Patrick Chung
- Board Member
- Evan Lovell
- Board Member
Evan is Chief Investment Officer of the Virgin Group and is responsible for managing the Virgin Group’s investment team and portfolio in North America. He also serves as CFO and Board Director for VG Acquisition Corp. In addition to those responsibilities Evan serves on the boards of Virgin Hotels, Virgin Voyages, Virgin Galactic, Virgin Orbit and BMR Energy. He also served on the board of Virgin America (formerly NASDAQ: VA) prior to its sale to Alaska Air Group, and on the board of AquaVenture Holdings (NYSE: WAAS).
Evan is a founding partner of the Virgin Green Fund, a private equity fund focused on the renewable energy and resource efficiency sectors. He is a seasoned private equity investor and operator having invested and participated in global private equity and M&A over the last 20 years. Prior to the Virgin Group, Evan was an investment professional at TPG Capital and served on the board of directors of a number of TPG Capital portfolio companies.
- Valerie Montgomery Rice
- Board member
Valerie Montgomery Rice, MD, FACOG, provides a valuable combination of experience at the highest levels of patient care and medical research, as well as organizational management and public health policy. Marrying her transformational leadership acumen and strategic thinking to tackle challenging management issues, she has a track record of redesigning complex organizations’ infrastructures to reflect the needs of evolving strategic environments and position the organization for success through sustainability tactics.
The sixth president of Morehouse School of Medicine (MSM) and the first woman to lead the freestanding medical institution, Montgomery Rice serves as the President and CEO. A renowned infertility specialist and researcher, she most recently served as Dean and Executive Vice President of MSM since 2011.
Prior to joining MSM, Montgomery Rice held faculty positions and leadership roles at various health centers, including academic health centers. Most notably, she was the founding director of the Center for Women’s Health Research at Meharry Medical College, one of the nation’s first research centers devoted to studying diseases that disproportionately impact women of color.
Dedicated to the creation and advancement of health equity, Montgomery Rice lends her vast experience and talents to programs that enhance pipeline opportunities for academically diverse learners, diversifies the physician and scientific workforce, and fosters equity in health care access and health outcomes. To this end, she holds memberships in various organizations and participates on a number of boards, such as the following: member, National Academy of Medicine and the Horatio Alger Association and board of directors for The Metro Atlanta Chamber, The Nemours Foundation, UnitedHealth Group, Westside Future Fund, Josiah Macy Jr. Foundation, and CARE. She also serves as an advisory board member for Headspace.
A Georgia native, Montgomery Rice holds a bachelor’s degree in chemistry from the Georgia Institute of Technology, a medical degree from Harvard Medical School, an honorary degree from the University of Massachusetts Medical School and a Doctor of Humane Letters honorary degree from Rush University. She completed her residency in obstetrics and gynecology at Emory University School of Medicine and her fellowship in reproductive endocrinology and infertility at Hutzel Hospital.
- Peter J. Taylor
- Board Member
Peter Taylor is the President of ECMC Foundation, a nonprofit corporation dedicated to educational attainment for low-income students. Under his leadership, he spearheaded more than $195 million of grants and investments in initiatives affecting educational outcomes for underserved students, with a focus on college success and career readiness.
Prior to his role leading the foundation, Peter served as Executive Vice President and Chief Financial Officer for the University of California system. Most of Peter’s professional career was in investment banking, with 16 years in municipal finance banking for Lehman Brothers and Barclays Capital, where he was managing director for the West Coast Fixed Income Group. Early in his career, he spent six years on the legislative staff of the California State Assembly Majority Leader working at the state capitol in Sacramento.
Active in the community, Peter also serves on several other boards including as a member of Edison International, Pacific Life, the Ralph M. Parsons Foundation and the Kaiser Family Foundation, where he chairs the Investment Committee. He previously served an appointee of Governor Jerry Brown to the Board of Trustees of the California State University system from 2015 - 2021, where he chaired the Educational Policy and Finance Committees. He was also President of the UCLA Alumni Association Board of Directors, the Chair of the James Irvine Foundation Board of Directors, the alumni representative on the UC Board of Regents, the Chair of the UCLA Foundation Board, a board member of the J. Paul Getty Trust where he chaired the Audit Committee, the Municipal Securities Rulemaking Board, and the California Community Foundation.
Peter received his undergraduate degree from UCLA, and a Master’s Degree in Policy Analysis from Claremont Graduate University. He is also a graduate from the Coro Program in Public Affairs, in Los Angeles.